Search results

Rituximab (MabThera®)

Follicular lymphoma in combination with CVP chemotherapy

rituximab (Mabthera)

Follicular lymphoma patients responding to induction therapy

rituximab (MabThera)

Relapsed/refractory CLL

rituximab (MabThera)

for the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy

rituximab (MabThera)

Treatment of patients with moderate to severe pemphigus vulgaris.

rituximab (Mabthera)

In combination with glucocorticoids for the induction of remission in adult patients with severe, active granulomatosis with polyangiitis (Wegener' s) (GPA) and microscopic polyangiitis (MPA).

rituximab subcutaneous (Mabthera)

For non-Hodgkin' s lymphoma (NHL) in adults: - previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy; - maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy; - treatment of patients with CD20 positive diffuse large B cell - non-Hodgkin's lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.

rituxumab (MabThera)

In combination with glucocorticoids, for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA).

Rituximab (MabThera®)

CD20 positive diffuse large B-cell non-Hodgkin's lymphoma

rituximab (MabThera)

Chronic Lymphocytic Leukaemia (CLL)

rituximab 10mg/ml concentrate for infusion (MabThera)

Relapsed/refractory follicular lymphoma

rituximab 100mg/10ml, 500mg/50ml ml solution for intravenous infusion (MabThera)

Severe active rheumatoid arthritis

ibrutinib (Imbruvica)

In combination with rituximab for the treatment of adult patients with Waldenström's macroglobulinaemia.

bendamustine (Levact)

Indolent non-Hodgkin's lymphomas as monotherapy in patients who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen.

Ibritumomab tiuxetan (Zevalin®)

Rituximab-relapsed or refractory CD20+ follicular B-cell non-Hodgkin's lymphoma.